[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-borderline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-borderline":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100054022","phase-1-egfr-targeted-photoimmunotherapy-with-asp-1929-for-locally-advanced-pancreatic-cancer-100054022",false,"NCT07698613","EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","BrUOG 438: EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed pancreatic adenocarcinoma.\n2. Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.\n3. Completed neoadjuvant chemotherapy\n4. Neoadjuvant radiation is allowed\n5. Planned surgical exploration\n6. Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.\n7. Patients with a history of biliary obstruction must have adequate biliary drainage.\n8. Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:\n\n   Platelet Count ≥ 75,000\u002Fmm3. Hemoglobin ≥ 8.0 g\u002FdL \\[NOTE: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g\u002FdL are not eligible\\] Absolute neutrophil count ≥ 1,000\u002Fmm3. \\[Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1\\] Alanine aminotransferase (ALT) ≤ 3×ULN Aspartate aminotransferase (AST) ≤ 3×ULN Total Bilirubin ≤ 1.5×ULN or \\\u003C 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) Creatinine ≤ 3×ULN\n9. Age ≥ 18\n10. ECOG performance status 0-1\n11. For women of pregnancy potential, a negative pregnancy test within 7 days prior to registration.\n12. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with distant metastases.\n2. Patients with medical co-morbidities that make them not candidates for surgical exploration\n3. Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929\n4. Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.\n5. History of significant (Grade ≥ 3) cetuximab infusion reactions\n6. Photosensitizing medications must be discontinued 4 weeks before ASP-1929 PIT treatment, unless medically required.\n7. No uncontrolled intercurrent illness including but not limited to symptomatic CHF, unstable angina, clinically significant severe cardiac arrhythmia, psychiatric illness or social situations that would limit compliance with study requirements.\n8. Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive ASP-1929 and\u002For be exposed to PIT illumination.\n9. Women who are pregnant or nursing.\n10. Patients with concomitant malignancies not expected to cause death within 5 years are eligible.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.",[27,28,29],"Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection","Pancreatic Cancer Borderline","Pancreatic Cancer Resectable",[31,32,33,34,35,36,37],"ASP-1929","photoimmunotherapy","EGFR targeting antibody","laser-light activable dye IR700","IRDye 700DX","RM-1929","cetuximab sarotalocan","NOT_YET_RECRUITING","2026-07-07",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":20},"2026-09",{"date":46,"type":20},"2033-09",{"name":48,"class":49},"Brown University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100638245","venous-resection-in-patients-undergoing-pancreatic-surgery-100638245","NCT07621029","Venous Resection in Patients Undergoing Pancreatic Surgery","Perioperative Factors Linked to Increased Risk for Thrombosis During Pancreatectomy With Venous Resection: the Influence of Technical Factors and Perioperative Antithrombotic Prophylaxis.","VENUS","Inclusion Criteria:\n\n* Patients undergoing curative pancreatic resection with simultaneous PV\u002FSMV resection; Any final pathology; Date of pancreatic surgery June 1st, 2026 - June 30th, 2027 (prospectively)\n\nExclusion Criteria:\n\n* Distant metastases (M1); Age \\\u003C18 years; R2 resection",{"count":60,"type":20},1000,"6 Months","OBSERVATIONAL","Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved. Pancreatectomy with vein resection (PVR) of the portal vein and the superior mesenteric vein (PV\u002FSMV) to address tumors with venous infiltration has become standard of care in pancreatic surgery for the past 20 years. Larger series and meta-analyses show that long-term survival beyond the 5-year threshold can be achieved with PVR, but with somewhat inferior survivor compared to standard pancreatic resections without venous resection. That is most likely due to the fact that tumors necessitating PVR are generally larger, less differentiated, and more likely to express unfavourable features such as perineural infiltration.\n\nRecent publications point out that PVR can be performed in pancreatic centers around the world with comparable morbidity and mortality, irrespective of the countries' income status. Also, benchmark outcomes for PVR in low-risk patients have been established, defining that the accepted risk for venous thrombosis should be lower than 14% at discharge. Despite that, a questionnaire among expert surgeons reveals that even if PVR is considered a standard procedure, surgeons are still concerned about significant morbidity. Also, the perception as to what proportion of patients require venous resection, how it should be performed and what anti-thrombotic prophylaxis should be given varies widely. The reported morbidity and thrombosis rates after different types of venous resections and reconstructions vary from under 2 to over 25%. There is no consensus as to which type of venous reconstruction is associated with most favourable short- and long-term outcomes, what specific surgical manoeuvres and graft materials decrease the overall complication and the vein-resection specific complications rates and what anti-thrombotic prophylaxis is safest (associated with lowest thrombosis rates and bleeding complications). Although some studies suggest that grafts are associated with higher thrombosis rates, there is no profound investigation as to how to avoid the use of grafts or, if necessary, what grafts are associated with least thrombotic risks while not causing increased patient morbidity.\n\nThe purpose of this study is to evaluate different technical manoeuvres, anti-thrombotic prophylaxis strategies and organisational features in a large cohort of patients undergoing PVR in median and large-volume centers in order to assess which factors contribute to vein resection-related specific morbidity.\n\nThe study design is an international multi-center observational cohort study, with retrospective and prospective part, including patients who underwent pancreatic surgery with PV\u002FSMV resection from 2018 to June 30 th 2025 and prospectively 18 months ahead. Perioperative factors, related to technical decisions, perioperative resuscitation, institutional organisational specificities, and anti-thrombotic prophylaxis, associated with increased risk for early (30-day), intermediate 30 days-6 months and late venous thrombosis (\\>6months) will be analysed. The thrombosis rate among the four types of venous reconstructions will be compared while adjusting for the length of the resected vein segment. Median and high-volume pancreatic centers (\\>20 pancreatic resected \u002Fyear).\n\nThe inclusion criteria are: patients undergoing radical pancreatic resection with simultaneous PV\u002FSMV resection, irrespective of final pathology operated between January 1 st 2018 - June 30 th, 2025 (retrospectively) or from July 1 st 2025-December 30 th, 2026 (prospectively). Patients with distant metastases (M1), \\\u003C18 years of age or undergoing R2 resection will be excluded.\n\nThe study intends to include over 1000 patients. The main objective is to assess the perioperative factors (technical, organisational, anti-thrombotic treatment) associated with increased risk for early (30 days), intermediate (\\>30 days-6 months) and late (\\>6 months) venous thrombosis.",[65,66,28,67],"IPMN, Pancreatic","Pancreatic Cancer, Resected","Chronic Pancreatitis",[69,70],"Pancreatic surgery","Venous resection","2026-05-27",{"date":73,"type":42},"2026-06-02",{"date":75,"type":20},"2026-06-01",{"date":77,"type":20},"2027-12-31",{"name":79,"class":49},"Sahlgrenska University Hospital"]